Streetbeat News

Regulatory

SPY

Federal Reserve's Neel Kashkari expressed hope that the Fed has done enough with its current interest rate policy. The statement suggests that there may not be significant changes in the interest rates in the near future.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:12 pm

SPY

Federal Reserve's Neel Kashkari has stated that he is unsure if the Fed's policy is restrictive enough. Despite this, consumer spending has remained robust and economic data suggests that the Fed is not as restrictive as it appears. The Fed is allowing the data to drive its decisions.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:07 pm

SPY

Minneapolis Fed President Neel Kashkari has stated that economic data suggests the Federal Reserve is not as restrictive as it appears, according to Reuters. This could potentially impact the broader market, including ETFs like SPY.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:07 pm

FEMY

Femasys has activated enrollment for its pivotal FemBloc trial at its first academic site in Brooklyn, New York. The trial will investigate the safety and efficacy of its investigational permanent birth control candidate.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:03 pm

SEEL

Seelos Therapeutics has announced preclinical data showing that treatment with SLS-005 resulted in a 46% reduction in Tau protein and an 18% reduction in NfL biomarker from baseline values within six months. The company will present these findings at Neuroscience 2023 from November 11-15.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:03 pm

SLE

Super League (NASDAQ:SLE) has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The company was previously not in compliance due to its common stock failing to meet the closing bid price of $1.00 or more for 30 consecutive business days.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:02 pm

NAOV

NanoVibronix has received approval for the inclusion of its UroShield products in the National Health Service (NHS) Prescription Services' Drug Tariff. This will allow the products to be prescribed and reimbursed by the NHS.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:01 pm

AMD

NVDA

China's Big Fund, aimed at bolstering the semiconductor industry, is struggling to meet its $41 billion target due to economic hardships and US restrictions. The fund, which has previously supported local chip giants and R&D initiatives, is now facing hesitancy from local governments and state-owned enterprises due to financial constraints and the current economic downturn. The fund remains committed to its five-year plan, with a focus on chipmaking equipment. US restrictions have affected Nvidia Corp and Advanced Micro Devices, Inc's chip sales to China.

Portfolio Pulse from Anusuya Lahiri

September 27, 2023 | 11:39 am

VBIV

VBI Vaccines has announced interim data from the Phase 1 study of its multivalent pan-coronavirus vaccine candidate, VBI-2901. The data suggests that peak responses were achieved with only a single 10µg dose of VBI-2901.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:34 am

SNSE

Sensei Biotherapeutics has initiated the combination therapy arm of the Phase 1/2 clinical trial for SNS-101, a cancer treatment, with the first patient being dosed. The trial involves a combination of SNS-101 with Regeneron's Libtayo.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 11:32 am